IMNP - Immune Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.052
-0.002 (-4.59%)
At close: 3:49PM EDT
Stock chart is not supported by your current browser
Previous Close0.054
Open0.056
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.051 - 0.063
52 Week Range0.040 - 1.050
Volume264,329
Avg. Volume600,003
Market Cap2.338M
Beta (3Y Monthly)2.02
PE Ratio (TTM)N/A
EPS (TTM)-1.342
Earnings DateJun 15, 2017 - Jun 16, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Immune Pharmaceuticals Announces Positive Preclinical Results in Asthma

    Immune Pharmaceuticals, Inc. (IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today positive results from a mouse study demonstrating that blockade of eotaxin-1 reduces lung inflammation and has a broader inhibitory effect on inflammatory cells than does blockade of interleukin (IL)-5. Overall, the anti-eotaxin-1 antibody produced a mean reduction of 22% in inflammatory cells in the BAL fluid, ranging from 17% to 26% across the four classes of inflammatory cells.  In contrast, IL-5 blockade reduced inflammatory cell counts by 19% with a 47% reduction in eosinophils but increases in neutrophils, macrophages and lymphocytes ranging from 31% to 77%.

  • GlobeNewswire11 days ago

    Immune Pharmaceuticals Announces $5 Million Financing

    Immune Pharmaceuticals, Inc. (IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it has entered into a Securities Purchase Agreement with an institutional investor in which it has sold $5.5 million in principal amount of Senior Secured Redeemable Convertible Debentures (the “Debentures”) for $2 million in cash and a $3 million promissory note to be funded upon the earlier of the effectiveness of a registration statement covering the resale of the issuable shares, or conversion of the Debentures. Dr. Fiorino went on to say, “I accepted the role of interim Chief Executive Officer because I believe that bertilimumab is a strategically attractive asset, and this funding provides us with runway to pursue that option.

  • GlobeNewswirelast month

    Immune Pharmaceuticals Provides a Corporate Update

    Immune Pharmaceuticals, Inc. (IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today provided a corporate update. “There have been many positive developments at Immune during this time of transition,” stated interim Chief Executive Officer Tony Fiorino, MD, PhD.  “The recent regulatory successes for bertilimumab underscore the progress that can be made with focus and execution.  I am proud of the dedication of our team and honored to work with them to move bertilimumab forward. An update on Immune’s manufacturing partnership with WuXi Biologics.  The tech transfer is well underway and the current timeline calls for the first 2,000 liter production run in the second half of 2019 and release of clinic-ready bertilimumab in a range of late 2019 through the second quarter of 2020.

  • GlobeNewswirelast month

    Bertilimumab Granted Fast Track Designation for the Treatment of Bullous Pemphigoid

    Immune Pharmaceuticals, Inc. (IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to bertilimumab for the treatment of bullous pemphigoid. “I am truly grateful that the FDA has granted Fast Track designation to bertilimumab for the treatment of bullous pemphigoid.

  • GlobeNewswirelast month

    Immune Pharmaceuticals Issues Statement on Former Chief Executive Officer

    Immune Pharmaceuticals, Inc. (IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today commented on a complaint filed by the Securities and Exchange Commission (the “SEC”) on September 8, 2018 in the United States District Court for the Southern District of New York against a number of individuals and entities, including the Company’s former Chief Executive Officer (“CEO”), alleging his involvement in a scheme to manipulate the stock price of an unnamed biotechnology company. None of the activities described in the SEC’s complaint involve the Company or the market for the Company’s common stock. Based on the information available to the Company, there is no evidence that any of the defendants, including the Company’s former CEO, attempted to manipulate the market for our common stock.  No participants in the Company’s financings completed during the former CEO’s tenure with the Company served or serve on Immune’s Board of Directors or in any position within the Company.  The Company will closely monitor the SEC case as it progresses.

  • GlobeNewswire2 months ago

    Bertilimumab Granted Orphan Drug Designation for the Treatment of Bullous Pemphigoid

    Immune Pharmaceuticals, Inc. (IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to bertilimumab for the treatment of bullous pemphigoid (BP). “We are incredibly gratified that bertilimumab has received Orphan Drug Designation for the treatment of bullous pemphigoid from the FDA and believe this designation, coupled with the recent positive opinion from the EMA’s Committee for Orphan Medicinal Products represent a significant regulatory milestone or bertilimumab,” commented Immune’s Chief Medical and Operating Officer, Tony Fiorino, MD, PhD.

  • GlobeNewswire3 months ago

    Immune Pharmaceuticals Postpones Special Meeting of Stockholders

    -Special Meeting of Stockholders scheduled for August 22, 2018 postponed-. -Company plans to appeal Nasdaq delisting determination-. ENGLEWOOD CLIFFS, N.J., Aug. 02, 2018-- Immune Pharmaceuticals, Inc., ...

  • GlobeNewswire3 months ago

    Immune Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for Bertilimumab for the Treatment of Bullous Pemphigoid

    Immune Pharmaceuticals, Inc. (IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on the Company’s application for Orphan Drug Designation for bertilimumab for the treatment of bullous pemphigoid (BP).

  • GlobeNewswire3 months ago

    Immune Pharmaceuticals Receives Nasdaq Delisting Determination; Eligible to trade Over-the-Counter July 26, 2018

    Immune Pharmaceuticals, Inc. (IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that it has received written notification from The Nasdaq Stock Market LLC ("Nasdaq") indicating that Nasdaq has determined to delist the Company's shares from The Nasdaq Capital Market due to the Company’s non-compliance with the minimum bid price requirement. The notification states that Nasdaq will suspend trading in the Company's shares effective with the open of business on July 26, 2018.

  • Reuters3 months ago

    BRIEF-WuXi Biologics, Immune Pharma Announce Development, Manufacturing Agreement For First-In-Class Monoclonal Antibody

    July 9 (Reuters) - Wuxi Biologics Cayman Inc: * WUXI BIOLOGICS AND IMMUNE PHARMACEUTICALS ANNOUNCE LATE-PHASE DEVELOPMENT AND MANUFACTURING PARTNERSHIP FOR A FIRST-IN-CLASS MONOCLONAL ANTIBODY * IMMUNE ...

  • ACCESSWIRE4 months ago

    Free Pre-Market Technical Recap on Sanofi and Three Additional Drug Makers Stocks

    On Thursday, July 05, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Thursday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Drug Manufacturers - Major equities this morning: Heron Therapeutics Inc. (NASDAQ: HRTX), Immune Pharmaceuticals Inc. (NASDAQ: IMNP), Johnson & Johnson (NYSE: JNJ), and Sanofi (NYSE: SNY).

  • Breakeven On The Horizon For Immune Pharmaceuticals Inc (NASDAQ:IMNP)
    Simply Wall St.5 months ago

    Breakeven On The Horizon For Immune Pharmaceuticals Inc (NASDAQ:IMNP)

    Immune Pharmaceuticals Inc’s (NASDAQ:IMNP): Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops therapeutic agents in the fields of immuno-inflammation, dermatology, and oncology. The company’s loss has recently broadened sinceRead More...

  • ACCESSWIRE5 months ago

    Breakfast Technical Briefing on Johnson & Johnson and Three Other Additional Healthcare Stocks

    Research reports have been issued by WallStEquities.com on Heron Therapeutics Inc. (NASDAQ: HRTX), Immune Pharmaceuticals Inc. (NASDAQ: IMNP), Johnson & Johnson (NYSE: JNJ), and Perrigo Co. PLC (NYSE: PRGO).

  • Is Immune Pharmaceuticals Inc (NASDAQ:IMNP) An Industry Laggard Or Leader?
    Simply Wall St.5 months ago

    Is Immune Pharmaceuticals Inc (NASDAQ:IMNP) An Industry Laggard Or Leader?

    Immune Pharmaceuticals Inc (NASDAQ:IMNP), a US$8.02M small-cap, operates in the healthcare industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as an aging population,Read More...

  • ACCESSWIRE6 months ago

    Wired News – Johnson & Johnson to Pay Compensatory Damages over Claims Linking Cancer to Asbestos in Talc

    Stock Monitor: Immune Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 10, 2018 / Active-Investors.com has just released a free research report on Johnson & Johnson (NYSE: JNJ ) ("J&J"). ...

  • Marketwired7 months ago

    Immune Pharmaceuticals Announces 2017 Financial Results

    Immune Pharmaceuticals, Inc. , a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced financial results for the year ...

  • Interested In Immune Pharmaceuticals Inc (NASDAQ:IMNP)? Here’s How It Performed Recently
    Simply Wall St.7 months ago

    Interested In Immune Pharmaceuticals Inc (NASDAQ:IMNP)? Here’s How It Performed Recently

    After reading Immune Pharmaceuticals Inc’s (NASDAQ:IMNP) most recent earnings announcement (30 September 2017), I found it useful to look back at how the company has performed in the past andRead More...